Clinical Recurrence Risk + Oncotype DX Score for Chemo Decisions

Moderators

Adding Clinical Risk of Recurrence to Oncotype DX Score Can Help Make Chemotherapy Decisions for Younger Women With Early-Stage Breast Cancer
June 14, 2019
Considering information about the clinical risk of recurrence of early-stage breast cancer along with the Oncotype DX Recurrence Score results can help refine which women age 50 and younger diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer that has not spread to the lymph nodes with a Recurrence Score of 16 to 25 will benefit from chemotherapy. Read more...